ArticleBreast cancer research : BCR2025
Morphological analysis of tumor microenvironment in HER2-positive breast cancer: predicting response to neoadjuvant chemotherapy on histopathological images.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Explainable AI-Derived Spatial Pathological Features of Tumor, Necrosis, and Lymphocytes Identify Key Histological Signatures for Residual Cancer Burden Assessment in Breast Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Swarm intelligence-guided ROI selection for deep learning assessment of HER2 in colorectal cancer.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHER2-positive breast cancer (HER2 + BC) is clinically distinct from other subtypes, such as triple-negative or hormone receptor–positive breast cancers, due to its unique tumor microenvironment (TME) and its heterogeneous response to neoadjuvant chemotherapy (NAC). Given the critical role of the TME in treatment outcomes, we investigated whether TME features extracted from histopathological images can predict pathological complete response (pCR) and guide personalized therapy.
methodsWe retrospectively analyzed 147 HER2 + BC patients treated with NAC, including 85 from the Yale Response dataset (training cohort) and 62 from the IMPRESS HER2+ dataset (external validation cohort). Hematoxylin and eosin-stained histopathology images were segmented using VGG-16 and Xception networks to generate tissue segmentation images (TS-images). Based on the TS-images, tumor and stroma regions were segmented. Intratumoral and stromal tumor-infiltrating lymphocytes (iTILs and sTILs, respectively) were extracted from these regions and then combined to form TILs. The morphological features of these regions were quantitatively characterized using connected component analysis. Feature selection was performed by integrating morphological and clinical data via the least absolute shrinkage and selection operator. The selected features were then used to train a multilayer perceptron model, which was validated on the IMPRESS HER2+ dataset.
resultsIn external validation, the model based on sTILs achieved an AUC of 0.873 for pCR prediction, with an F1 score of 0.889, PPV of 0.821, recall of 0.970, and NPV of 0.933. This performance substantially outperformed models trained on stroma (AUC = 0.779), tumor (0.732), iTILs (0.594), and TILs (0.668). Notably, the sTILs-based model maintained high performance (AUC = 0.722) even when trained with 20% of the training cohort. Univariate analyses identified morphological predictors for pCR, including the filled area of significant regions (mean) in sTILs (P value = 0.015).
conclusionMorphological TME features from histopathological images can accurately predict pCR in HER2 + BC, supporting their use in guiding NAC decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.